Genmab Says European Commission Grants Marketing Authorization for Tivdak as Cervical Cancer Treatment

MT Newswires Live03-31

Genmab (GMAB) said Monday that the European Commission has granted marketing authorization for Tivdak as a treatment for adult patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy.

The company said the approval was based on data from a phase 3 trial that met its primary endpoint of overall survival, with Tivdak demonstrating a 30% reduction in risk of death compared with chemotherapy.

Tivdak, also known as tisotumab vedotin, is co-developed and co-commercialized by Genmab and Pfizer (PFE) globally, with Pfizer holding its marketing authorization in the European Union until its transfer to Genmab within the year, according to the statement.

Price: 19.56, Change: -0.34, Percent Change: -1.73

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment